Clinical and laboratory characteristics among the patients with TA-TMA
| Characteristics . | Derivation cohort (n = 269) . | Validation cohort (n = 238) . | P* . |
|---|---|---|---|
| Clinical characteristics | |||
| Sex | .369 | ||
| Male | 161 (59.9) | 133 (55.9) | |
| Female | 108 (40.1) | 105 (44.1) | |
| Age at HSCT, median (range), y | 26 (3-62) | 29 (1-66) | .328 |
| Age at TA-TMA diagnosis, median (range), y | 26 (3-62) | 30 (1-67) | .334 |
| Time from HSCT to TA-TMA, median (IQR), d | 68 (42-143) | 59 (35-103) | .004 |
| Underlying disease | |||
| AML | 95 (35.3) | 91 (38.2) | .519 |
| ALL | 103 (38.3) | 74 (31.1) | .094 |
| CML | 18 (6.7) | 4 (0.2) | .007 |
| MDS/MPN | 32 (11.9) | 32 (13.4) | .688 |
| Other | 21 (7.8) | 37 (15.5) | .008 |
| HCT-CI | |||
| 0 | 196 (72.9) | 182 (76.5) | .360 |
| 1-2 | 66 (24.5) | 48 (20.2) | .244 |
| ≥3 | 7 (2.6) | 8 (3.4) | .794 |
| Donor type | |||
| Matched related | 28 (10.4) | 23 (9.7) | .883 |
| HLA-partially matched related | 239 (88.8) | 210 (88.2) | .889 |
| Matched unrelated | 2 (0.7) | 5 (2.1) | .261 |
| ABO compatibility | |||
| ABO matched | 141 (52.4) | 140 (58.8) | .153 |
| ABO mismatched | 128 (47.6) | 98 (41.2) | .153 |
| Conditioning regimen | |||
| BU/CY | 32 (11.9) | 29 (12.2) | 1.000 |
| BU/CY+ATG | 213 (79.2) | 191 (80.3) | .825 |
| TBI-based regimen | 12 (4.5) | 8 (3.4) | .649 |
| Other | 12 (4.5) | 10 (4.2) | 1.000 |
| Stem cell source | BM+PBSC | BM+PBSC | |
| GVHD prophylaxis | |||
| CsA+mycophenolate+MTX | 201 (74.7) | 202 (84.9) | .008 |
| Tacrolimus/sirolimus | 68 (25.3) | 36 (15.1) | .008 |
| Time to platelet engraftment, median (IQR), d† | 15 (12-22) | 15 (12-22) | .591 |
| Time to WBC engraftment, median (IQR), d† | 13 (11-16) | 13 (12-16) | .463 |
| Acute GVHD prior to TMA | |||
| None | 72 (26.7) | 74 (31.1) | .326 |
| I-II | 135 (50.2) | 105 (44.1) | .182 |
| III-IV | 62 (23.0) | 59 (24.8) | .677 |
| Donor lymphocyte infusion | 55 (20.4) | 38 (16.0) | .207 |
| Laboratory characteristics | |||
| Anemia (Hb < 70 g/L) | 128 (47.6) | 139 (58.4) | .016 |
| Thrombocytopenia (platelet count < 15 000/μL) | 131 (48.7) | 114 (47.9) | .859 |
| Elevated TBIL (>1.5 times ULN) | 162 (60.2) | 123 (51.7) | .060 |
| Hypoalbuminemia (<28 g/L) | 77 (28.6) | 75 (31.5) | .498 |
| Proteinuria (≥30 mg/dL) | 102 (37.9) | 101 (42.4) | .319 |
| Outcomes | |||
| 6-mo mortality rate | 125 (46.5) | 98 (41.2) | .245 |
| 1-y mortality rate | 129 (48.0) | 108 (45.4) | .593 |
| Characteristics . | Derivation cohort (n = 269) . | Validation cohort (n = 238) . | P* . |
|---|---|---|---|
| Clinical characteristics | |||
| Sex | .369 | ||
| Male | 161 (59.9) | 133 (55.9) | |
| Female | 108 (40.1) | 105 (44.1) | |
| Age at HSCT, median (range), y | 26 (3-62) | 29 (1-66) | .328 |
| Age at TA-TMA diagnosis, median (range), y | 26 (3-62) | 30 (1-67) | .334 |
| Time from HSCT to TA-TMA, median (IQR), d | 68 (42-143) | 59 (35-103) | .004 |
| Underlying disease | |||
| AML | 95 (35.3) | 91 (38.2) | .519 |
| ALL | 103 (38.3) | 74 (31.1) | .094 |
| CML | 18 (6.7) | 4 (0.2) | .007 |
| MDS/MPN | 32 (11.9) | 32 (13.4) | .688 |
| Other | 21 (7.8) | 37 (15.5) | .008 |
| HCT-CI | |||
| 0 | 196 (72.9) | 182 (76.5) | .360 |
| 1-2 | 66 (24.5) | 48 (20.2) | .244 |
| ≥3 | 7 (2.6) | 8 (3.4) | .794 |
| Donor type | |||
| Matched related | 28 (10.4) | 23 (9.7) | .883 |
| HLA-partially matched related | 239 (88.8) | 210 (88.2) | .889 |
| Matched unrelated | 2 (0.7) | 5 (2.1) | .261 |
| ABO compatibility | |||
| ABO matched | 141 (52.4) | 140 (58.8) | .153 |
| ABO mismatched | 128 (47.6) | 98 (41.2) | .153 |
| Conditioning regimen | |||
| BU/CY | 32 (11.9) | 29 (12.2) | 1.000 |
| BU/CY+ATG | 213 (79.2) | 191 (80.3) | .825 |
| TBI-based regimen | 12 (4.5) | 8 (3.4) | .649 |
| Other | 12 (4.5) | 10 (4.2) | 1.000 |
| Stem cell source | BM+PBSC | BM+PBSC | |
| GVHD prophylaxis | |||
| CsA+mycophenolate+MTX | 201 (74.7) | 202 (84.9) | .008 |
| Tacrolimus/sirolimus | 68 (25.3) | 36 (15.1) | .008 |
| Time to platelet engraftment, median (IQR), d† | 15 (12-22) | 15 (12-22) | .591 |
| Time to WBC engraftment, median (IQR), d† | 13 (11-16) | 13 (12-16) | .463 |
| Acute GVHD prior to TMA | |||
| None | 72 (26.7) | 74 (31.1) | .326 |
| I-II | 135 (50.2) | 105 (44.1) | .182 |
| III-IV | 62 (23.0) | 59 (24.8) | .677 |
| Donor lymphocyte infusion | 55 (20.4) | 38 (16.0) | .207 |
| Laboratory characteristics | |||
| Anemia (Hb < 70 g/L) | 128 (47.6) | 139 (58.4) | .016 |
| Thrombocytopenia (platelet count < 15 000/μL) | 131 (48.7) | 114 (47.9) | .859 |
| Elevated TBIL (>1.5 times ULN) | 162 (60.2) | 123 (51.7) | .060 |
| Hypoalbuminemia (<28 g/L) | 77 (28.6) | 75 (31.5) | .498 |
| Proteinuria (≥30 mg/dL) | 102 (37.9) | 101 (42.4) | .319 |
| Outcomes | |||
| 6-mo mortality rate | 125 (46.5) | 98 (41.2) | .245 |
| 1-y mortality rate | 129 (48.0) | 108 (45.4) | .593 |
Unless otherwise noted, data are n (%).
ALL, acute lymphoblastic leukemia; AML, acute myeloblastic leukemia; BM, bone marrow; CML, chronic myeloid leukemia; Hb, hemoglobin; IQR, interquartile range; MDS, myelodysplastic syndrome; MPN, marrow proliferative neoplasm; PBSC, peripheral blood stem cell; TBI, total body irradiation; WBC, white blood cell.
Comparison between the derivation cohort and the validation cohort.
WBC and platelet engraftment: a neutrophil granulocyte count ≥500 per microliter and a platelet count ≥ 50 000 per microliter for 3 consecutive days without transfusions, respectively.